The 18 Wall Street analysts covering Definium Therapeutics, Inc. hold a median 12-month price target of $70 — +87.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 3 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Definium Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Growth (25): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (23): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DFTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +87.1% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Sept 2026 | Baird | Maintains | Outperform | $75 → $79 |
| 15 Sept 2026 | Canaccord Genuity | Maintains | Buy | $64 → $78 |
| 14 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $70 |
| 14 Sept 2026 | Needham | Reiterates | Buy | $66 |
| 11 Sept 2026 | RBC Capital | Reiterates | Outperform | $66 |
| 18 Aug 2026 | B of A Securities | Initiates | Buy | — |
| 18 Aug 2026 | B of A Securities | Initiates | Buy | $75 |
| 14 Aug 2026 | Maxim Group | Maintains | Buy | — |
| 13 Aug 2026 | Baird | Maintains | Outperform | — |
| 13 Aug 2026 | Baird | Maintains | Outperform | $57 → $75 |
| 13 Aug 2026 | Canaccord Genuity | Maintains | Buy | $58 → $64 |
| 13 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 13 Aug 2026 | Jones Trading | Maintains | Buy | $74 → $90 |
| 13 Aug 2026 | Jones Trading | Maintains | Buy | — |
| 13 Aug 2026 | RBC Capital | Maintains | Outperform | $57 → $66 |
| 13 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 13 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 13 Aug 2026 | Wells Fargo | Maintains | Overweight | $68 → $72 |
| 12 Aug 2026 | Needham | Maintains | Buy | — |
| 12 Aug 2026 | Needham | Maintains | Buy | $50 → $66 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DFTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 2 Oct 2026, Definium Therapeutics, Inc. returned +206.1% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 18% of US stocks
Cheaper than 91% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 18% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Definium Therapeutics, Inc. has a market value of $5.0B and an enterprise value of $4.0B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$353.8M.
Free cash flow in the twelve months to 30 June 2026: −$168.0M.
Trailing P/E: −18.2×; forward P/E: −19.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Definium Therapeutics, Inc. employs 105 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Definium Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Definium Therapeutics announced inducement grants of options to purchase an aggregate of 334,810 common shares, issued to fifteen newly hired non-executive employees with grant dates in September.
Why it matters — DFTX watchers may care as the inducement grants reflect the company onboarding new non-executive employees, potentially signaling workforce growth and incentive-based hiring activity.
Definium Therapeutics' Chief Medical Officer Dan Karlin stated that recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder and major depressive disorder following a single treatment. Longer-term open-label portions of the studies remain underway.
Why it matters — A positive Phase III readout for DT120 in both anxiety and depression could represent a significant clinical milestone for Definium's lead pipeline candidate.
Definium Therapeutics reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder. The single-dose treatment met its primary endpoint and all key secondary endpoints, adding to previously reported positive pivotal-study results in GAD and major depressive disorder.
Why it matters — This strengthens the clinical evidence supporting DT120 and could be a meaningful advancement for Definium's pipeline in anxiety and depression indications.
Definium Therapeutics reported success in a second Phase III trial for its Generalized Anxiety Disorder program, with DT120 ODT showing significant anxiety improvements. This result paves the way for FDA discussions and a planned 2027 regulatory filing.
Why it matters — A second Phase III win advances the DT120 ODT program toward regulatory submission, a key milestone for Definium's anxiety disorder pipeline.
Definium Therapeutics, Inc. (DFTX) held a discussion covering topline results from its Panorama Phase 3 study of DT120 ODT in generalized anxiety disorder, as presented in a Seeking Alpha transcript. The item is a transcript of that discussion of the study's topline findings.
Why it matters — A DFTX watcher would care because the Panorama Phase 3 topline results for DT120 ODT are a key clinical milestone for the company's pipeline in generalized anxiety disorder.
The 18 Wall Street analysts covering Definium Therapeutics, Inc. have a median 12-month price target of $70, with estimates ranging from $55 to $91. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering Definium Therapeutics, Inc., 18 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Definium Therapeutics, Inc. 41 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Oct 2026, Definium Therapeutics, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +87.1% from the last close, and Ticker Nerd's factor model ranks Definium Therapeutics, Inc. 41 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Definium Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DFTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $91 over the next 12 months.
Definium Therapeutics, Inc. returned +206.1% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Definium Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders.
The most recent item we track (Business Wire, 28 Sept 2026): "Definium Therapeutics Announces New Employee Inducement Grants". Definium Therapeutics announced inducement grants of options to purchase an aggregate of 334,810 common shares, issued to fifteen newly hired non-executive employees with grant dates in September.
Definium Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders. The company’s current pipeline centers on psychiatry and neurology, with lead product candidates such as DT120, an orally disintegrating tablet under late-stage study for generalized anxiety disorder and major depressive disorder, and DT402, which is being evaluated for autism spectrum disorder. Definium Therapeutics applies a research-driven approach to psychedelic-derived and other brain-health-focused therapeutics, aiming to address underlying causes of psychiatric and neurological conditions. The company operates from New York and serves the healthcare and biotechnology markets through its drug development programs and clinical research activities.
CEO Mr. Robert Barrow · 105 employees · United States · https://definiumtx.com
